Literature DB >> 31648328

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Manali Kamdar1, Hongli Li2, Robert W Chen3, Lisa M Rimsza4, Michael L Leblanc2, Timothy S Fenske5, Thomas C Shea6, Paul M Barr7, Tycel J Phillips8, John P Leonard9, Brad S Kahl10, Jonathan W Friedberg11, Sonali M Smith12.   

Abstract

Entities:  

Year:  2019        PMID: 31648328      PMCID: PMC6849956          DOI: 10.1182/bloodadvances.2019000526

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  12 in total

1.  Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

Authors:  Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

2.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

Authors:  Christiane Pott; Eva Hoster; Marie-Helene Delfau-Larue; Kheira Beldjord; Sebastian Böttcher; Vahid Asnafi; Anne Plonquet; Reiner Siebert; Evelyne Callet-Bauchu; Niels Andersen; Jacques J M van Dongen; Wolfram Klapper; Françoise Berger; Vincent Ribrag; Achiel L van Hoof; Marek Trneny; Jan Walewski; Peter Dreger; Michael Unterhalt; Wolfgang Hiddemann; Michael Kneba; Hanneke C Kluin-Nelemans; Olivier Hermine; Elizabeth Macintyre; Martin Dreyling
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

3.  Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Authors:  Steven Le Gouill; Catherine Thieblemont; Lucie Oberic; Anne Moreau; Krimo Bouabdallah; Caroline Dartigeas; Gandhi Damaj; Thomas Gastinne; Vincent Ribrag; Pierre Feugier; Olivier Casasnovas; Hacène Zerazhi; Corinne Haioun; Hervé Maisonneuve; Roch Houot; Fabrice Jardin; Eric Van Den Neste; Olivier Tournilhac; Katell Le Dû; Franck Morschhauser; Guillaume Cartron; Luc-Matthieu Fornecker; Danielle Canioni; Mary Callanan; Marie C Béné; Gilles Salles; Hervé Tilly; Thierry Lamy; Remy Gressin; Olivier Hermine
Journal:  N Engl J Med       Date:  2017-09-28       Impact factor: 91.245

4.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

5.  Incidence and survival trends in mantle cell lymphoma.

Authors:  Narendranath Epperla; Mehdi Hamadani; Timothy S Fenske; Luciano J Costa
Journal:  Br J Haematol       Date:  2017-04-25       Impact factor: 6.998

Review 6.  Mantle Cell Lymphoma.

Authors:  Chan Yoon Cheah; John F Seymour; Michael L Wang
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

7.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

8.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad Kahl; Peter Wood; Tim Hawkins; David MacDonald; David Simpson; Kathryn Kolibaba; Samar Issa; Julie Chang; Judith Trotman; Doreen Hallman; Ling Chen; John M Burke
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

9.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

10.  Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

Authors:  Yuhong Zhou; Haijun Wang; Wenjing Fang; Jorge E Romaguer; Yanxia Zhang; Kay B Delasalle; Larry Kwak; Qing Yi; Xianglin L Du; Michael Wang
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

View more
  6 in total

Review 1.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

Review 2.  Hematopoietic cell transplantation for mantle cell lymphoma.

Authors:  Masamitsu Yanada; Kazuhito Yamamoto
Journal:  Int J Hematol       Date:  2022-01-29       Impact factor: 2.490

3.  Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.

Authors:  David A Bond; Jeffrey M Switchenko; Diego Villa; Kami Maddocks; Michael Churnetski; Alina S Gerrie; Subir Goyal; Krithika Shanmugasundaram; Oscar Calzada; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Brian T Hill; Yazeed Sawalha; Peter Martin; Edward Maldonado; Max Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; Talha Badar; Jin Guo; Mehdi Hamadani; Timothy S Fenske; Mary-Kate Malecek; Brad S Kahl; Christopher R Flowers; Kristie A Blum; Jonathon B Cohen
Journal:  Blood Adv       Date:  2021-12-14

4.  Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.

Authors:  Diego Villa; Laurie H Sehn; Kerry J Savage; Cynthia L Toze; Kevin Song; Wendie D den Brok; Ciara L Freeman; David W Scott; Alina S Gerrie
Journal:  Blood Adv       Date:  2020-08-11

5.  Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.

Authors:  Alessia Castellino; Yucai Wang; Melissa C Larson; Matthew J Maurer; Brian K Link; Umar Farooq; Andrew L Feldman; Sergei I Syrbu; Thomas M Habermann; Jonas Paludo; David J Inwards; Thomas E Witzig; Stephen M Ansell; Cristine Allmer; Susan L Slager; Jonathon B Cohen; Peter Martin; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood Adv       Date:  2022-02-22

Review 6.  Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).

Authors:  Hrvoje Lalic; Igor Aurer; Drago Batinic; Dora Visnjic; Tomislav Smoljo; Antonija Babic
Journal:  Oncol Rep       Date:  2022-05-04       Impact factor: 4.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.